7 March 2024 11:00 GMT
Notice of Annual General
Meeting
AstraZeneca PLC (the Company)
announced today the publication of its Notice of Annual General
Meeting 2024 and Shareholders' Circular (the Notice).
The Company's Annual General Meeting
(AGM) will be digitally-enabled and will be held on Thursday 11
April at 14:30 (BST). Full details and joining instructions are set
out in the Notice.
The Notice, proxy form and 2020
Performance Share Plan have been submitted to the National Storage
Mechanism and will shortly be available for inspection at
https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
The Notice is also available on the Company's website at
www.astrazeneca.com/noticeofmeeting2024.
The Notice is being despatched to
shareholders today.
The business to be conducted at the
AGM is summarised below:
1. To receive the
Company's Accounts, the Reports of the Directors and Auditor and
the Strategic Report for the year ended 31 December 2023
2. To confirm the 2023
interim dividends
3. To re-appoint
PricewaterhouseCoopers LLP as Auditor
4. To authorise the
Directors to agree the remuneration of the Auditor
5. To elect or re-elect
Directors
6. To approve the annual
statement of the Chair of the Remuneration Committee and the Annual
Report on Remuneration for the year ended 31 December
2023
7. To approve the
Directors' Remuneration Policy
8. To approve amendments
to the AstraZeneca Performance Share Plan 2020
9. To authorise limited political donations
10. To authorise the Directors to
allot shares
11. To authorise the Directors to
disapply pre-emption rights
12. To authorise the Directors to
further disapply pre-emption rights for acquisitions and specified
capital investments
13. To authorise the Company to
purchase its own shares
14. To
reduce the notice period for general meetings
Pursuant to Regulation 41 of the
Uncertificated Securities Regulations 2001, only holders of
ordinary shares entered in the register of members of the Company
by 6.30pm (BST) on 9 April 2024 (or their duly appointed proxies),
or if this meeting is adjourned, in the register of members by
6.30pm (BST) two days prior to any adjourned meeting, are entitled
to attend or vote at the AGM in respect of the number of ordinary
shares registered in their name at that time. Changes to the
entries in the register of members after 6.30pm (BST) on 9 April
2024, or if this meeting is adjourned, in the register of members
after 6.30pm (BST) two days prior to any adjourned meeting, shall
be disregarded in determining the rights of any person to attend or
vote at the AGM. The Record Date applied to
the Euroclear Sweden system to determine entitlement to participate
and vote at the AGM is close of business on 2 April
2024.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global,
science-led biopharmaceutical company that focuses on the
discovery, development, and commercialisation of prescription
medicines in Oncology, Rare Diseases, and BioPharmaceuticals,
including Cardiovascular, Renal & Metabolism, and Respiratory
& Immunology. Based in Cambridge, UK, AstraZeneca operates in
over 100 countries and its innovative medicines are used by
millions of patients worldwide. Please visit astrazeneca.com and
follow the Company on social media @AstraZeneca.
Contacts
For details on how to contact the
Investor Relations Team, please click here.
For Media contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC